HypertensionRandomised controlled trial
Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension
- Randomised controlled trial
- 2-arm
- pragmatic
Authors' conclusion
In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension.
Study context
- Population
- Primary care patients with left ventricular hypertrophy (LVH) on prior echocardiogram, no established cardiomyopathy and no antihypertensive treatment, Mass General Brigham, 2023–2024
- Participants
- 648 patients
- Comparison
- Intervention vs Control
- Interventionn = 326
- Controln = 322reference
- Primary endpoint
- Initiation of an antihypertensive medication
- Follow-up
- 12 months
Primary result
As reported in the abstract
Adjusted odds ratio
3.76
95% CI 2.09–6.75
P < 0.001
Events by treatment group
Intervention vs Control
adjusted OR 3.76 (95% CI 2.09–6.75); P < 0.001
Secondary outcomes
| Outcome | adjusted OR (95% CI) | P value | |
|---|---|---|---|
| New hypertension diagnosis | 4.43 (2.36–8.33) | P < 0.001 | |
| 0.10.31310Adjusted odds ratio (log scale) |
Cardiomyopathy diagnosis
- No significant difference between groups
Original publication
Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension. JAMA Cardiol. Published 1 July 2025. doi:10.1001/jamacardio.2025.0871
Summarised from the published abstract; every number is checked against it